Medicsen is a startup that works in an artificial, non-invasive pancreas for those suffering from diabetes. It is capable of predicting future glucose values for the patient an hour ahead of time with a margin of error of less than 10 glucose units, while at the same time providing practical lifestyle advice to control illness.
Eduardo W. Jørgensen, César de Mercado, Patricia Cremades and José Carlos Montesinos are the drivers behind this initiative, all of them involved in the world of medicine and technology.
Medicsen is comprised of two pieces of technology that can function independently: the software, which predicts future glucose levels and provides lifestyle advice to the patient through a chat-type app, and the hardware and physical environment that administers the pharmaceuticals through the skin with no injections.
In 2023, these two pieces will be integrated to automate the treatment of patients with chronic illness, making it a non-invasive artificial pancreas. At this time, Medicsen offers annual software licenses for patient risk management to private insurers. In terms of the investment needed to launch the device, the founders achieved around 800 thousand euros of financing. The sum raised is allocated, practically in full, to research and development of the tools. Only 10% has been invested in dissemination and international relations strategies.